Relative to baseline, the fructokinase inhibitor (PF-06835919) led to a 26.5% reduction in liver fat, an 11.5% reduction in fasting uric acid, and a trend for improvements of other cardiometabolic parameters, including insulin resistance and inflammation [82]. This evidence concerns the gene KHK and Insulin resistance.